Vanderbilt Researchers Launch Clinical Trial Testing GLP-1 Drugs for Opioid Addiction

Researchers at Vanderbilt University have launched a clinical trial to determine whether GLP-1 receptor agonist medications, commonly prescribed for diabetes and obesity, could also help treat opioid use disorder by preventing relapse in patients receiving buprenorphine therapy.

The double-blind, randomized, placebo-controlled study represents one of the first controlled investigations into whether drugs like semaglutide and similar GLP-1 compounds could address the craving and reward mechanisms that drive opioid addiction. While these medications have transformed treatment for diabetes and weight management, emerging evidence suggests they may also reduce substance cravings by acting on brain pathways involved in addiction.

How the Vanderbilt Study Works

The trial will enroll 31 participants who are at least 18 years old, have been diagnosed with opioid use disorder, and began buprenorphine treatment within the past 80 days. Researchers selected this population because the early phase of medication-assisted treatment represents a critical window when relapse risk remains elevated.

"There is a critical need to address treatment options for all individuals with opioid use disorder," said Jessica Young, who is leading the Vanderbilt study. "Opioid use disorder is a chronic disease where relapse is common. Finding ways to prevent relapse for both men and women is lifesaving."

Participants will meet with researchers weekly for six months while receiving either an active GLP-1 medication or placebo alongside their standard buprenorphine regimen. The study design aims to capture whether adding the GLP-1 drug produces measurable improvements in treatment retention and reduced opioid use compared to buprenorphine alone.

The Science Behind GLP-1 and Addiction

GLP-1 receptor agonists work by mimicking a hormone that regulates appetite and blood sugar, but research suggests these drugs also affect reward pathways in the brain that are implicated in addiction. Preliminary observational studies have indicated that patients taking GLP-1 medications for diabetes or weight loss may experience reduced cravings for alcohol, nicotine, and other substances.

The mechanism appears to involve modulation of dopamine signaling in the brain's reward centers—the same pathways that opioids hijack to produce euphoria and drive compulsive use. By potentially dampening the intensity of cravings and the reward associated with drug use, GLP-1 drugs could provide a pharmacological bridge during the vulnerable early recovery period.

"We hope to find that adding a GLP-1 to treatment plans will help people stabilize on buprenorphine therapies and prevent relapse," Young said. "This could change the standard of care if it improves outcomes and decreases relapse."

Broader Context of Addiction Treatment Innovation

The Vanderbilt trial arrives as the addiction treatment field increasingly explores repurposing existing medications to expand the limited pharmacological options for substance use disorders. Currently, only three medications—methadone, buprenorphine, and naltrexone—are FDA-approved specifically for opioid use disorder, and a substantial percentage of patients discontinue treatment within the first six months.

The study also reflects growing recognition that medication-assisted treatment works best when combined with approaches targeting the neurobiological mechanisms of craving and relapse. If GLP-1 medications prove effective, they could represent the first new pharmacological approach to opioid addiction in years.

While researchers caution that the Vanderbilt study involves a relatively small sample size and will require replication in larger trials, the investigation could lay groundwork for a significant expansion of treatment options. The completion of the six-month trial is expected to provide initial data on whether this class of medications, already used safely by millions for metabolic conditions, could become a valuable tool in addressing the nation's ongoing opioid crisis.